Erich Schlick is one of a very few European scientists/drug developers to see their innovation become a blockbuster. This happened in the 1990s when he initiated the development of Humira, the first fully human therapeutic monoclonal antibody.
Erich joined Wellington as an Investment Partner for Life Sciences in October 2005. Before this, he served as Director and Head of 3i Healthcare Germany and as Deputy Sector Head 3i Healthcare Worldwide and was responsible for numerous successful investments.
Prior to venture capital, Erich spent 15 years with BASF Pharma Knoll AG, 10 years thereof as an executive board member with worldwide responsibility for preclinical and clinical R&D. During this time, he obtained worldwide registrations for five products in cardiovascular, metabolic and pain indications. In 1993, he established the partnership with Cambridge Antibody Technology (CAT), which led to the successful development of Humira.
Erich studied medicine and specialised in pharmacology. He holds a professorship of immunopharmacology at the University of Heidelberg/Mannheim